Sweden

KAND567: a candidate to counteract COVID-19 and heart attack hyperinflammation

Kancera, the Swedish company developing drugs to block hyperinflammation and protect function of vital organs, has commenced a phase 2 clinical trial of KAND567, a drug candidate which antagonizes the fractalkine receptor believed to trigger life-threatening inflammatory processes in COVID-19 and heart attack patients.

KAND567: a candidate to counteract COVID-19 and heart attack hyperinflammation Read More »